Ana Maria Barragan Montero

Dr. Ana Maria Barragan Montero

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2021 in Physica Medica
Verified
Journal Article
Closed access
AMAna Maria Barragan Montero
Ana Maria Barragan Montero
UJUmair Javaid
Umair Javaid
GVGilmer Valdés
Gilmer Valdés
DNDan Nguyen
Dan Nguyen
PDPaul Desbordes
Paul Desbordes
JLJohn A. Lee
John A. Lee

27 May 2022 in Physics in Medicine & Biology
Verified
Journal Article
Open access
AMAna Maria Barragan Montero
Ana Maria Barragan Montero
ABAdrien Bibal
Adrien Bibal
MDMargerie Huet Dastarac
Margerie Huet Dastarac
CDCamille Draguet
Camille Draguet
GVGilmer Valdés
Gilmer Valdés
JLJohn A Lee
John A Lee
The interest in machine learning (ML) has grown tremendously in recent years, partly due to the performance leap that occurred with new techniques of deep learning, convolutional neural networks for images, increased computational power, and wider availability of large datasets. Most fields of medicine follow that popular trend and, notably, radiation oncology is one of those that are at the forefront, with already a long tradition in using digital images and fully computerized workflows. ML models are driven by data, and in contrast with many statistical or physical models, they can be very large and complex, with countless generic parameters. This inevitably raises two questions, namely, the tight dependence between the models and the datasets that feed them, and the interpretability of the models, which scales with its complexity. Any problems in the data used to train the model will be later reflected in their performance. This, together with the low interpretability of ML models, makes their implementation into the clinical workflow particularly difficult. Building tools for risk assessment and quality assurance of ML models must involve then two main points: interpretability and data-model dependency. After a joint introduction of both radiation oncology and ML, this paper reviews the main risks and current solutions when applying the latter to workflows in the former. Risks associated with data and models, as well as their interaction, are detailed. Next, the core concepts of interpretability, explainability, and data-model dependency are formally defined and illustrated with examples. Afterwards, a broad discussion goes through key applications of ML in workflows of radiation oncology as well as vendors’ perspectives for the clinical implementation of ML.

1 March 2021 in Physica Medica
Verified
Journal Article
Closed access
AMAna Maria Barragan Montero
Ana Maria Barragan Montero
MTMelissa Thomas
Melissa Thomas
GDGilles Defraene
Gilles Defraene
SMSteven Michiels
Steven Michiels
KHKarin Haustermans
Karin Haustermans
ESEdmond Sterpin
Edmond Sterpin

12 September 2022 in Physics in Medicine & Biology
Verified
Journal Article
Open access
ABAaron Babier
Aaron Babier
RMRafid Mahmood
Rafid Mahmood
BZBinghao Zhang
Binghao Zhang
VAVictor G L Alves
Victor G L Alves
AMAna Maria Barragan Montero
Ana Maria Barragan Montero
TCTimothy C Y Chan
Timothy C Y Chan
Objective. To establish an open framework for developing plan optimization models for knowledge-based planning (KBP). Approach. Our framework includes radiotherapy treatment data (i.e. reference plans) for 100 patients with head-and-neck cancer who were treated with intensity-modulated radiotherapy. That data also includes high-quality dose predictions from 19 KBP models that were developed by different research groups using out-of-sample data during the OpenKBP Grand Challenge. The dose predictions were input to four fluence-based dose mimicking models to form 76 unique KBP pipelines that generated 7600 plans (76 pipelines × 100 patients). The predictions and KBP-generated plans were compared to the reference plans via: the dose score, which is the average mean absolute voxel-by-voxel difference in dose; the deviation in dose-volume histogram (DVH) points; and the frequency of clinical planning criteria satisfaction. We also performed a theoretical investigation to justify our dose mimicking models. Main results. The range in rank order correlation of the dose score between predictions and their KBP pipelines was 0.50–0.62, which indicates that the quality of the predictions was generally positively correlated with the quality of the plans. Additionally, compared to the input predictions, the KBP-generated plans performed significantly better ( P < 0.05; one-sided Wilcoxon test) on 18 of 23 DVH points. Similarly, each optimization model generated plans that satisfied a higher percentage of criteria than the reference plans, which satisfied 3.5% more criteria than the set of all dose predictions. Lastly, our theoretical investigation demonstrated that the dose mimicking models generated plans that are also optimal for an inverse planning model. Significance. This was the largest international effort to date for evaluating the combination of KBP prediction and optimization models. We found that the best performing models significantly outperformed the reference dose and dose predictions. In the interest of reproducibility, our data and code is freely available.

24 September 2022 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
CDCamille Draguet
Camille Draguet
AMAna Maria Barragan Montero
Ana Maria Barragan Montero
MVMacarena Chocan Vera
Macarena Chocan Vera
MTMelissa Thomas
Melissa Thomas
PPPieter Populaire
Pieter Populaire
ESEdmond Sterpin
Edmond Sterpin

10 March 2020 in Medical Physics
Verified
Journal Article
Open access
PDF file
GBGregory Buti
Gregory Buti
KSKevin Souris
Kevin Souris
AMAna Maria Barragan Montero
Ana Maria Barragan Montero
MCMarie Cohilis
Marie Cohilis
JLJohn A. Lee
John A. Lee
ESEdmond Sterpin
Edmond Sterpin
Purpose: Robust optimization is a computational expensive process resulting in long plan computation times. This issue is especially critical for moving targets as these cases need a large number of uncertainty scenarios to robustly optimize their treatment plans. In this study, we propose a novel worst‐case robust optimization algorithm, called dynamic minimax, that accelerates the conventional minimax optimization. Dynamic minimax optimization aims at speeding up the plan optimization process by decreasing the number of evaluated scenarios in the optimization.Methods: For a given pool of scenarios (e.g., 63 = 7 setup × 3 range × 3 breathing phases), the proposed dynamic minimax algorithm only considers a reduced number of candidate‐worst scenarios, selected from the full 63 scenario set. These scenarios are updated throughout the optimization by randomly sampling new scenarios according to a hidden variable P, called the “probability acceptance function,” which associates with each scenario the probability of it being selected as the worst case. By doing so, the algorithm favors scenarios that are mostly “active,” that is, frequently evaluated as the worst case. Additionally, unconsidered scenarios have the possibility to be re‐considered, later on in the optimization, depending on the convergence towards a particular solution. The proposed algorithm was implemented in the open‐source robust optimizer MIROpt and tested for six four‐dimensional (4D) IMPT lung tumor patients with various tumor sizes and motions. Treatment plans were evaluated by performing comprehensive robustness tests (simulating range errors, systematic setup errors, and breathing motion) using the open‐source Monte Carlo dose engine MCsquare.Results: The dynamic minimax algorithm achieved an optimization time gain of 84%, on average. The dynamic minimax optimization results in a significantly noisier optimization process due to the fact that more scenarios are accessed in the optimization. However, the increased noise level does not harm the final quality of the plan. In fact, the plan quality is similar between dynamic and conventional minimax optimization with regard to target coverage and normal tissue sparing: on average, the difference in worst‐case D95 is 0.2 Gy and the difference in mean lung dose and mean heart dose is 0.4 and 0.1 Gy, respectively (evaluated in the nominal scenario).Conclusions: The proposed worst‐case 4D robust optimization algorithm achieves a significant optimization time gain of 84%, without compromising target coverage or normal tissue sparing.